Centocor files PLA for the cardiac imaging agent March 31. Centocor said that clinical studies have been conducted in about 1,000 patients during the past three and one-half years. Potential indications include detection of post-heart attack cardiac damage, diagnosing myocarditus and diagnosing heart transplant rejection.
You may also be interested in...
Internal FDA emails obtained by the Environmental Working Group through a FOIA request indicate that the agency was moving toward rulemaking in 2016 to restrict or prohibit use of formaldehyde in heated hair-straightening cosmetics, but seemingly abandoned the initiative. That has Congress, NGOs and other stakeholders asking questions and renewing calls for cosmetics regulatory reform.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.